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INTRODUCTION
Acute encephalopathy sometimes occurs in the
early stages of severe infectious diseases with
pyrexia, impaired consciousness, convulsions or sei-
zures associated with brain edema (1, 2). The an-
tecedent infection of acute encephalopathy is often
viral, mainly influenza virus and HHV-6 (human
herpes virus-6) (3, 4), though many other viruses
can also been involved, such as adenovirus and Cox-
sackie virus. According to a nation-wide clinical sur-
vey of influenza-associated encephalopathy (IAE)
in Japan, IAE patients do not only show brain edema
but also develop multi-organ failure, and the con-
dition is associated with high mortality (31.8%) and
disability (27.7%) rates (5). Clinical and genetic stud-
ies in such IAE patients have demonstrated the pres-
ence of high fever-induced disorder of mitochon-
drial fatty acid β -oxidation caused by heat-inacti-
vation of carnitine palmitoyltransferase II (CPT II)
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(EC 2.3.1.21) (MIM#600650), a pivotal component
of ATP generation through mitochondrial fatty acid
β -oxidation (4, 6-8).
The human CPT II is a homotetramer encoded
by a single CPT II gene, which spans 20 kb, con-
tains 5 exons ranging from 81 to 1,305 bp, and is
located on chromosome 1p32. CPT II deficiency is
the most common inherited disease of energy me-
tabolism and has three distinct clinical forms : a neo-
natal form, which results in sudden death, and two
less severe forms, the early-onset infantile and late-
onset adult forms (9-13). Several studies have ex-
amined the potential relationships among the geno-
types of CPT II deficiency and their clinical pheno-
types or their impact on fuel utilization (14, 15).
We reported recently that the majority of fatal and
handicapped IAE patients exhibited transiently ele-
vated serum acylcarnitine ratio [(C16 : 0+C18 : 1)/
C2]0.048 the upper cutoff value, particularly0.09,
suggesting secondary CPT II deficiency and im-
paired energy metabolism during high-grade fever,
despite the asymptomatic disorders of CPT II in
daily life (6). Analyses of genotype and allele compo-
sitions of CPT II in a large number of patients with
severe IAE showed the predominance of a thermo-
labile phenotype of CPT II mutations, [c.1055TG
(p.F352C)], in East Asians, and its compound form
[c.1055TG (p.F352C)]+[c.1102GA (p.V368I)]
(6, 7). The mutations [c.1102GA (p.V368I)] and
[c.1939AG (p.M647V)] have no effect on enzyme
activity and its thermolability (7).
The present investigation is an extension to the
above study and was designed to characterize the
enzymatic properties of CPT II mutations in a pa-
tient with adenovirus-associated encephalopathy and
members of his family. To characterize the CPT II
phenotypes of the patient and family, CPT2 with
various mutations were expressed in COS-7 cells,
and the activities, thermal instability and half-lives
of CPT II were analyzed and compared with those
of the wild type (WT) CPT II.
MATERIALS AND METHODS
Materials
L-[methyl-3H] carnitine, L-[35S] methionine, ECL-
Plus detection reagents were purchased from Am-
ersham Pharmacia Biotech (Piscataway, NJ). BCA
reagent was obtained from Pierce (Rockford, IL).
ABI DyeDeoxy Terminator Cycle Sequencing Kit
was from PE-Applied Biosystems (Foster, CA).
Anti-CPT II (H-300, sc-20671) was from Santa Cruz
Biotech (Delaware, CA).
Expression of WT and mutant CPT IIs in COS-7
cells
Genomic DNA was purified from whole blood
kindly provided by Dr. K Maruyama, from the Cen-
tral Hospital, Aichi Prefectural Colony. This inves-
tigation was approved by the ethics review com-
mittee for human genome analysis at our institu-
tion. A full-length WT human CPT II cDNA clone
(hCPT2 Genbank accession number NM_000098)
containing the entire coding region was a kind gift
from Dr. V. Esser, from the University of Texas.
Plasmid pCMV6-WT was used as a parental vector
to generate full-length mutant CPT II cDNA clones,
pCMV6-Q216R [c.647AG (p.Q216R)], pCMV6-
Q216R+V368I+M647V [c.647AG (p.Q216R) ;
c.1102GA (p.V368I) and c.1939AG (p.M647V)],
pCMV6-Q216R+G249EfsX16 [c.647AG (p.Q216R)
and c.745delG (p.G249EfsX16)] and pCMV6-G249
EfsX16 [c.745delG (p.G249EfsX16)] using the
QuickChange Site - Directed Mutagenesis Kit
(Stratagene, La Jolla, CA). CPT2 exons 1 - 5 of
genomic DNA were amplified by PCR and se-
quenced as described previously (7). The primers
used for mutations induction are listed in Table 1.
All substitutions and integrity of the CPT2 cDNAs
were confirmed by sequence analysis.
COS-7 cells (2106) cultured at 37in 5% CO2
in low-glucose Dulbecco’s modified Eagle’s essen-
tial medium (DMEM) (Invitrogen, Grand Island,
Table 1. Primers used for construction of CPT2 mutants.
Region Forward primer Reverse primer
Q216R 5’ - tatcccctggatatgtcccggtattttcggcttttc-3’ 5’ -gaaaagccgaaaataccgggacatatccaggggata-3’
G249EfsX16 5’ -ctcctggtcctaaggaaagaaatttttatatcttt -3’ 5’ -aaagatataaaaatttctttccttaggaccaggag-3’
V368I 5’ -gatggctctactgccatccactttgagcactcttg-3’ 5’ -caagagtgctcaaagtggatggcagtagagccagc-3’
M647V 5’ -aaggccttagaagacgtgtttgatgccttagaagg-3’ 5’ -ccttctaaggcatcaaacacgtcttctaaggcctt -3’
Reference sequences are GenBannk accession number NC_000001 for human CPT II genomic DNA. GenBank accession number
NM_000098 for WT human CPT II. The mutant sites appear bold and underlined.
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NY) containing 10% fetal calf serum (FCS) (Roche
Molecular Biochemicals, Indianapolis, IN) were
used for transfection. WT and mutant CPT2 cDNAs
(6 μg each) were transfected into COS-7 cells by
FuGENE 6 transfection reagent (Roche Diagnostics
Co. Indianapolis, IN) using the instructions pro-
vided by the manufacturer. After transfection for 72
h, cells were washed twice with calcium and mag-
nesium- free phosphate-buffered saline [PBS(-)],
lysed with 0.5 ml of CPT II reaction buffer (5 mM
Tris-HCl buffer, pH 7.4, containing 0.1% Tween 20
and 0.5 M KCl) and then centrifuged at 147,600g
for 1 h at 4. pSVβ -Galactosidase control vector
(Promega, Madison, WI) was co-transfected into
COS-7 cells with various pCMV6-CPT2 plasmids
as an internal standard for the monitoring of trans-
fection efficiency. Mock transfection was also car-
ried out as a control.
Western blot analysis of CPT II expression
WT and CPT II mutant proteins overexpressed in
COS-7 cells were analyzed by SDS-polyacrylamide
gel electrophoresis (PAGE) under reducing condi-
tions, followed by western immunoblotting. Cell
lysates were applied onto 10-20% SDS-PAGE gra-
dient gels according to the method of Laemmli (16).
After electrophoresis, proteins in the gels were
transferred electrophoretically on to polyvinyldene
difluoride (PVDF) membranes. Excess sites on the
membrane were blocked by incubation with 3% (w/
v) non - fat dried skimmed milk in TBS (Tris-buff-
ered saline ; 20 mM Tris-HCl, pH 7.5, and 150 mM
NaCl) for 2 h at room temperature. After washing
once with TBS, the membranes were incubated with
0.4 μg/ml of anti -CPT II antibodies (H -300, sc-
20671, Santa Cruz Biotech, Delaware, CA) in TBS/
0.05% Tween 20 (TTBS) by incubation overnight at
4. Then the membranes were washed three times
with TTBS and incubated with 0.3 μg/ml horserad-
ish-peroxidase-labelled anti-rabbit IgG (Sigma, St.
Louis, MO) in 3% (w/v) non-fat dried skimmed milk
in TBS for 1 h at room temperature. Immunoreac-
tive proteins were visualized using the enhanced
chemiluminescence (ECL) detection system (Am-
ersham Biosciences, Piscataway, NJ) using the pro-
tocol provided by the manufacturer. The amounts
of CPT II proteins were normalized to the amount
of β -actin proteins.
Immunoprecipitate and amino acid sequence analy-
sis
COS-7 cells were transfected with CPT2 WT
and mutant cDNAs expression plasmids. After 72 h,
the cell lysates were immunoprecipitated with 3
μg anti-CPT II antibody (H-300, sc-20671, Santa
Cruz Biotech) and applied onto 10-20% SDS-PAGE
gradient gels. After electrophoresis, proteins in the
gels were transferred electrophoretically on to PVDF
membranes. To identify and characterize the expres-
sion, we analyzed amino acid sequences of these
mutant proteins. N-terminal amino acid sequences
of immunoprecipitated CPT II proteins were deter-
mined using an Applied Biosystems model 492 gas-
phase sequencer/140C system and the instructions
provided by the manufacturer.
Assay of CPT II activity and thermal instability
CPT II activities in the lysates of COS-7 cells
transfected with WT and mutant CPT2 cDNAs were
measured at 30for 2 h, by detecting palmitoyl-
L-[methyl-3H] carnitine formed from 200 μM L-
[methyl-3H] carnitine and 50 μM palmitoyl-CoA as
described previously (17). The formed palmitoyl-L-
[methyl-3H] carnitine was extracted with 1-butanol
and the radioactivity was counted by liquid Scintil-
lation Counter (model LS 6500, Beckman, Fullerton,
CA). To analyze the heat stability of WT and CPT II
mutants, 100 μl of the cell lysates were preincubated
at 41or 30for 2 h, and the enzyme activities
were then measured by the addition of 200 μM L-
[methyl-3H] carnitine followed by incubation at 30
for 2 h. Protein concentrations in the cell lysate were
measured using bicinchoninic acid (BCA) protein
assay reagent kit (Pierce, Rockford, IL).
Half-life of WT and mutant CPT IIs
Half-life of WT and CPT II mutants in transfected
COS-7 cells was analyzed as described previously
(7). COS-7 cells (2105) in 35 mm dishes were
transfected with CPT2 WT and mutant cDNAs ex-
pression plasmids (1 μg each). After 48 h, the cells
were washed and incubated with serum- and me-
thionine-free medium for 30 min, followed by a
pulse labeling with 370 MBq 35S-methionine (spe-
cific activity 1000 Ci/mM) for 2 h. After labeling,
cells were washed twice with PBS (-) at 37and
then incubated with low-glucose DMEM containing
10% FCS and 2 mMmethionine to chase for 0, 1, 3,
6, 12 and 18 h. At various chase intervals, the cells
were lysed with 0.5 ml RIPA buffer (10 mM Tris-
HCl, pH 7.5, containing 1% Nonidet P - 40, 0.05%
SDS, 0.5% sodium deoxycholate, 1 mM EDTA, 150
mM NaCl, and protease inhibitors cocktail) and
were immunoprecipitated with 3 μg anti-CPT II
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antibody (H -300, sc - 20671, Santa Cruz Biotech)
coupled to rec-Protein G-Sepharose 4B (Zymed
Laboratories, San Francisco, CA) by incubation over-
night at 4under constant shaking. Immunopre-
cipitates were separated by 10-20% SDS-PAGE un-
der reducing conditions and the dried gels were ana-
lyzed by autoradiography.
RESULTS
CPT II mutations in a patient with adenovirus-
associated encephalopathy and family members
Genotype analysis by the five exons PCR and se-
quence check of CPT2 in the patient with adenovi-
rus-associated encephalopathy showed heterozy-
gous compound mutations ; heterozygous mutation
[c.647AG (p.Q216R)] on one allele and heterozy-
gous mutation [c.745delG (p.G249EfsX16)] on an-
other allele, which caused a frame shift resulting
in a premature termination codon (p.G249EfsX16).
The mother had homozygous mutation [c.647AG
(p.Q216R)], while the father had heterozygous mu-
tation [c.745delG (p.G249EfsX16)] on one allele and
heterozygous mutations [c.1102GA (p.V368I)+
c.1939AG (p.M647V)] on the other allele, and
the sister had heterozygous mutation [c.647AG
(p.Q216R)] on one allele and heterozygous muta-
tions [c.1102GA (p.V368I)+c.1939AG (p.M647
V)] on the other allele (Table 2). Among these
mutations, [c.647AG (p.Q216R)] and [c.745delG
(p.G249EfsX16)] were novel missense mutations
and did not match more than 25 mutations reported
thus far in CPT II deficiency of late-onset muscu-
lar, infantile/juvenile hepatic and severe neonatal
phenotypes (15, 18-26).
In vitro expression and western blot analysis
To characterize these CPT2 mutations, we ex-
pressed WT and CPT II mutants by transfection in
COS-7 cells : pCMV6-WT, single mutants pCMV6-
Q216R and pCMV6-G249EfsX16, and double com-
pound mutant pCMV6-Q216R+G249EfsX16. This
was based on the location of V368I and M647V near
the acylcarnitine binding sites, though have little ef-
fects on Km values (7). The triple compound mu-
tant, pCMV6-Q216R+V368I+M647V, was prepared
to analyze the effects of mutations of V368I and
M647V on the novel mutant Q216R. Western im-
munoblotting analysis of the overexpressed pCMV6-
WT, pCMV6-Q216R and pCMV6-Q216R+V368I+
M647V which encoded 658 amino acids, showed a
single protein band with a molecular mass of 67
kDa. On the other hand, the overexpressed pCMV6-
Q216R+G249EfsX16 and pCMV6-G249EfsX16 en-
coded 264 amino acids, showed a faint single protein
band with 27 kDa (Fig. 1). The amounts of CPT II
proteins expressed in the cell lysates were normal-
ized to that of the internal control (β -actin).
Immunoprecipitate and amino acid sequence analy-
sis
To characterize the CPT II of the patient, the cell
lysates of COS-7 cells pretransfected with pCMV6-
WT, pCMV6-Q216R, pCMV6-G249EfsX16, and the
Table 2. Identified CPT2 mutations in the patient and family members.
Kindred Nucleotide change Amino acid change Mutation type Exon Ref.
mother, sister, patient c.647AG p.Q216R Missense 4 current study
father, patient c.745delG p.G249EfsX16 Frameshift 4 current study
father, sister c.1102GA p.V368I Missense 4 6, 7, 13
father, sister c.1939AG p.M647V Missense 5 6, 7, 13
Fig. 1. Expression of WT and mutant CPT IIs in COS-7cells.
The expression levels of WT and mutant CPT IIs of the patient
and his family in COS-7 cells after transfection for 72 h was ana-
lyzed by western immunoblotting with anti -CPT II antibody. The
amount of CPT II protein in the cell lysate was normalized to
the amount of β -actin as an internal control. Data are represen-
tative results of three separate experiments.
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compound form pCMV6-Q216R+G249EfsX16 were
immunoprecipitated with anti-CPT II antibody. The
resulting immunoprecipitates were applied onto 10-
20% SDS-PAGE gradient gel under reducing condi-
tions and the proteins in the gels were transferred
electrophoretically onto PVDF membranes (Fig. 2).
The N-terminal 10 residues of immunoprecipitated
CPT II protein bands with a molecular mass of 27
kDa were analyzed. Both 27 kDa protein bands
from pCMV6 -G249EfsX16 and pCMV6 -Q216R+
G249EfsX16 showed the sequence alignment,
K69PLLN DGQFR78, although the N-terminal se-
quences of the 67 kDa mature CPT II proteins from
WT, pCMV6-Q216R and pCMV6-Q216R+V368I+
M647V showed S26AGSGPGQYL35 (GenBank acces-
sion number NP_000089). These results suggest
that the N-terminal 43 residues of these deletion
mutant CPT II proteins were removed additionally
in COS-7 cells, probably during the course of pro-
teolytic maturation of CPT II.
Activity and thermal instability of CPT II mutations
WT and four mutant CPT2 cNDAs found in the
patient and his family were transfected into COS-7
cells : pCMV6-WT, pCMV6-Q216R, pCMV6-Q216R+
V368I+M647V, pCMV6-G249EfsX16 and pCMV6-
Q216R+G249EfsX16. The specific activities of
pCMV6-WT and pCMV6-Q216R, pCMV6-Q216R+
V368I+M647V, pCMV6-Q216R+G249EfsX16, pCMV
6 -G249EfsX16 and control vector pCMV6 were
0.560.05, 0.470.05, 0.380.05, 0.0650.01,
0.0650.01 and 0.0650.01 nmol/min/mg protein
(n=5), respectively (Fig. 3).
We have reported previously a thermolabile mu-
tation of F352C CPT II in patients with severe IAE
(6). To evaluate the thermal instability of the mu-
tations identified in the patient’s family, lysates of
COS-7 cells expressing these CPT II mutants were
pre-incubated under high temperature of 41for
2 h as well as under stable condition at 30, and
then CPT II activities were measured at 30by
the addition of substrates L-carnitine and palmitoyl-
CoA. Mild thermal instability of pCMV6-Q216R was
detected at 41and the instability was markedly
enhanced at 41by the additional compound mu-
tations of V368I and M647V, although that of WT
was well maintained at above 90% under the same
conditions. No enzyme activities were observed in
the CPT II mutants of pCMV6-G249EfsX16 and
pCMV6-Q216R+G249EfsX16 in comparison of the
enzyme activities of cells transfected with the vector
alone.
Half-lives of CPT II mutants
To analyze the intracellular stability of the CPT
II mutants, COS-7 cells transfected with WT and
four mutant CPT2 cNDAs found in the patient and
family were metabolically labeled with L-[35S] me-
thionine and the half-lives of mutants and WT CPT
IIs were analyzed in a pulse-chase protocol (Fig. 4).
There was no significant difference in the protein la-
beling efficiency among WT CPT II, Q216R CPT II
and Q216R+V368I+M647V CPT II, suggesting simi-
lar rates of protein synthesis in WT and these CPT
II mutants in COS-7 cells. However, the labeling ef-
ficiencies of CPT II mutants, Q216R+G249EfsX16
CPT II and G249EfsX16 CPT II, were markedly
Fig. 2. Immunoprecipitation of mutant CPT IIs over-expressed
in COS-7 cells and their N-terminal amino acid sequence analy-
sis. Mutant CPT IIs in COS-7 cells expressed by transfection
with pCMV6 -WT, pCMV6 -Q216R, pCMV6 -Q216R +V368I +
M647V, pCMV6-Q216R+G249EfsX16, and pCMV6-G249EfsX16
were immunpprecipitated with anti -CPT II antibody. The N-
terminal amino acid sequences were determined using an Applied
Biosystems model 492 gas-phase sequencer/140C system.
Fig. 3. Enzyme activity and thermal instability of CPT II mu-
tants in COS-7 cells transfected with WT and mutant CPT2
cDNAs. To analyze the thermal instability, the lysates of COS-7
cells transfected with WT or mutant CPT2 cDNAs were prein-
cubated at 30 and 41 for 2 h. Then enzyme reactions were
started by the addition of substrates at 30 for 2 h. Data are
meanSD of five different experiments.
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lower than those of WT, suggesting that mRNAs of
these mutants are unstable and the rates of synthe-
sis of CPT II are low. Pulse-labeling and chase ex-
periments demonstrated the longest half-life in WT
CPT II (T1/2 17 h), compared with 11 h and 3.5 h
for pCMV6 - Q216R and pCMV6 -Q216R+V368I+
M647V mutants, respectively. Furthermore, the half-
lives of the deletion mutants of pCMV6 -Q216R+
G249EfsX16 and pCMV6 -G249EfsX16 were the
shortest with a T1/21 h.
DISCUSSION
Acute encephalopathy is caused by various vi-
ruses and often accompanied by febrile convulsions
or seizures with severe brain edema. There is no
specific relationship between the viruses and the
type of encephalopathy ; the pathogenesis of acute
encephalopathy is probably mediated primarily by
host factors. The mechanisms underlying encepha-
lopathy and multiple organ failure are vascular hy-
perpermeability and the subsequent severe edema
affecting the brain and various organs (27). The
brain capillary endothelium is characterized by a
greater density of mitochondria than that of periph-
eral capillaries (28) and fatty acid oxidation in mi-
tochondria is the major energy source at about 70%
of the ATP generation particularly in the endothelial
cells (29). These findings well explain that a large
proportion of patients with fatal and handicapped
IAE have high fever-related disorder of mitochon-
drial fatty acid β -oxidation caused by heat- inactiva-
tion of CPT II, an important component of ATP gen-
eration through mitochondrial fatty acid β -oxidation
(6-8).
In the present report, we characterized CPT II
mutations found in adenovirus-associated encephalo-
pathy in a patient who had repeated attacks of en-
cephalopathy several times a year from 9 months to
Fig. 4. Pulse-chase (left) and half - lives (right) of WT and mutant CPT IIs in COS-7 cells. After transfection, the cells were pulse-
labeled with L-[35S] methionine for 2 h and then chased for 0, 1, 3, 6, 12, and 18 h as described in Materials and Methods. Mutant
CPT IIs in the cell lysates were immunoprecipitated with anti -CPT II antibody, then subjected to SDS-PAGE followed by autora-
diography.
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4-year and 9 months of age. Genomic CPT2 analy-
sis of the patient and his family revealed two new
mutations : the first was heterozygous mutation
[c.647AG (p.Q216R)], which caused mild thermal
instability, and the second heterozygous mutation
was deletion [c.745delG (p.G249EfsX16)], which
caused a frame shift resulting in a premature ter-
mination codon and silencing of enzyme activity.
The father had another missense mutation of V368I
and M647V. The sister had mutation of Q216R on
one allele and V368I and M647V on the other allele.
In this regard, a previous study showed that the
V386I and/or M647V mutation lead to further re-
duction in enzyme activity in conjunction with the
F352C mutation, although these mutants by them-
selves only slightly reduced the activity (7). In this
study, we analyzed the negative effects the V386I
and/or M647V mutation on the novel Q216R CPT
II mutant, and showed that additional compound
mutations of V386I and M647V to Q216R enhanced
thermal instability of CPT II with Q216R (Fig. 3).
Furthermore, we also analyzed the additional effect
of Q216R mutation on the half-life of deletion mu-
tant [c.745delG (p.G249EfsX16)] (Fig. 4).
CPT II protein is a homotetramer encoded by a
single gene, CPT2 . CPT II activities in the leuko-
cytes of the patient and his father with [c.745delG
(p.G249EfsX16)] mutation on one allele, was about
half or less than half of WT CPT II activities
(Yamaguchi M, manuscript submitted for publica-
tion), probably because the full length CPT II pro-
tein of 67 Kda from one allele, but not CPT II pro-
tein of 27 Kda, contributes to the enzyme activity.
The significantly lower labeling efficiency with L-
[35S] Met of 27 kDa CPT II fragment protein than
those of full-length 67 kDa mutant CPT IIs at 0-time
in the chase experiments (Fig. 4) indicates that the
rate of 27 kDa CPT II protein synthesis was signifi-
cantly lower than that of 67 kDa CPT IIs. This might
be due to accelerated degradation of mutant RNAs of
minigene, as reported previously by Gong et al. (30).
Furthermore, the N-terminal 43 residues of the
newly synthesized 27 kDa CPT II were removed and
showed the sequence K69PLLN DGQFR78. The re-
sults also suggest potential instability of the mutant
protein in COS-7 cells. The half-lives of these de-
letion mutants of pCMV6-Q216R+G249EfsX16 and
pCMV6-G249EfsX16 were the shortest with a T1/2
1 h. There was no significant effect of Q216R mu-
tation on the half-life of deletion mutant [c.745delG
(p.G249EfsX16)] (Fig. 4).
CPT II deficiency is one of the most common
inborn errors of fatty acid oxidation and CPT II is an
important enzyme for ATP production (31, 32). De-
pletion of ATP in endothelial cells weakens interac-
tions between tight junction proteins, such as oc-
cluding and ZO-1, and the intracellular cytoskeleton,
which control the permeability of the blood-brain
barrier (33, 34). The phenotypic manifestations of
ATP depletion appear suddenly when ATP levels fall
below a threshold value (35). The clinical manifes-
tations of sudden-onset brain edema in patients with
virus-associated encephalopathy support the hy-
pothesis of an ATP threshold in the etiology of that
edema. The thermal instability and short T1/2 of the
novel CPT II mutations identified in our study might
play important roles in reducing ATP levels below
the phenotypic threshold in brain endothelial cells
of patients with virus-induced brain encephalopathy,
particularly those with hyperpyrexia.
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